Bobby Gaspar, CEO of Orchard Therapeutics, has said the company's gene therapy, Libmeldy, for rare and fatal MLD is priced reasonably compared ...
https://www.google.com/url?rct=j&sa=t&url=https://www.fiercepharma.com/pharma/england-s-price-watchdog-rejects-orchard-s-pricey-gene-therapy-for-metachromatic&ct=ga&cd=CAIyGmEyNDJjNTAxZWU3OTQyNzI6Y29tOmVuOlVT&usg=AFQjCNFs7t1e6ho_ZwosWaokTFzt09WTrQ
No comments:
Post a Comment
Note: Only a member of this blog may post a comment.